ZURICH--Roche Holding AG (ROG.VX) and the Breast International Group Monday announced final results from the Phase III HERA trial, which confirmed that one year of Herceptin (trastuzumab) treatment remains the standard of care for people with early-stage HER2-positive breast cancer.
- These data showed that there was no difference in the time women lived without their disease returning (disease-free survival) when they received Herceptin for two years versus one year, a secondary endpoint of the study.
- After a median follow-up of eight years, the improvements in disease-free survival and overall survival for women who received Herceptin for one year remained statistically significant compared to women who underwent observation alone.
- There were no new safety findings in the study
-Zurich Bureau, Dow Jones Newswires, +41 43 443 80 47; email@example.com